ProSavin

ProSavin is an experimental drug believed to be of use in the treatment of Parkinson's Disease. It is administered to the striatum in the brain, inducing production of dopamine.[1]

It is manufactured by Oxford BioMedica, who plan to start European Phase I and Phase II clinical trials in 2007. Animal trials have been a success, with dopamine levels restored without the side effects associated with other current treatments for Parkinson's,[2] in particular, without the jerky involuntary movements associated with current drugs.[3]

Mechanism of Action

Prosavin uses Oxford BioMedica's Lentivector delivery system to transfer three genes, aromatic amino acid dopa decarboxylase, tyrosine hydroxylase and GTP-cyclohydrolase 1, to the striatum in the brain, reprogramming transduced cells to secrete dopamine.[4] https://archive.is/20140316165827/http://www.oxfordbiomedica.co.uk/prosavin-r/

See also

References

  1. ↑ Oxford BioMedica. Drug Information Page. Retrieved on March 29, 2007.
  2. ↑ Daily Telegraph. Investor Information. Retrieved on March 29, 2007.
  3. ↑ Ben Hirschler (2009-10-14). "Long-term monkey tests back Oxford's gene therapy". Reuters. Retrieved 2009-10-14.
  4. ↑ Oxford BioMedica . Drug Advanced Information Page. Retrieved on April 5, 2007.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.